Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2021 | BMT CTN 1302: maintenance ixazomib following alloHCT in patients with high-risk myeloma

Taiga Nishihori • 20 May 2021
ASCO 2021
Multiple Myeloma Bortezomib Fludarabine Ixazomib Melphalan
BMT CTN 1302

Taiga Nishihori, MD, Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the results from the Phase II BMT CTN 1302 trial (NCT02440464) of maintenance ixazomib after allogeneic hematopoietic cell transplantation in patients with high-risk multiple myeloma. Fludarabine, melphalan and bortezomib were administered as a conditioning treatment and 12 rounds of ixazomib or placebo maintenance were administered after transplant. Dr Nishihori reports no significant progression-free survival (PFS) or overall survival (OS) between the ixazomib and placebo groups. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Taiga Nishihori, MD has received research support from Novartis and Karyopharm.

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals